Condition
Conjunctival Neoplasms
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05645341Completed
Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface
NCT03515954CompletedPrimary
AS-OCT Guided Treatment of Diffuse CSCC
NCT00456495Phase 1CompletedPrimary
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Showing all 3 trials